These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25404016)

  • 1. Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.
    Mabuchi H; Nohara A
    Nat Rev Endocrinol; 2015 Jan; 11(1):8-9. PubMed ID: 25404016
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Santos RD; Watts GF
    Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
    [No Abstract]   [Full Text] [Related]  

  • 3. Dyslipidaemia: Evolocumab lowers LDL cholesterol.
    Huynh K
    Nat Rev Cardiol; 2014 Dec; 11(12):687. PubMed ID: 25331087
    [No Abstract]   [Full Text] [Related]  

  • 4. [PCSK9 inhibition--A new era in cholesterol treatment].
    Olsson A
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PCSK9 in familial hypercholesterolaemia.
    Sijbrands EJ
    Lancet; 2012 Jul; 380(9836):6-7. PubMed ID: 22633823
    [No Abstract]   [Full Text] [Related]  

  • 8. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
    N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 12. PCSK9 inhibitors.
    Farnier M
    Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Milazzo L; Antinori S
    N Engl J Med; 2012 Jun; 366(25):2425; author reply 2426. PubMed ID: 22716983
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].
    Bailén Almorox R
    Rev Clin Esp; 2012 Jul; 212(7):408-9. PubMed ID: 22937541
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Banerjee Y; Shah K; Al-Rasadi K
    N Engl J Med; 2012 Jun; 366(25):2425-6; author reply 2426. PubMed ID: 22716984
    [No Abstract]   [Full Text] [Related]  

  • 16. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
    Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
    Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.
    Davidson MH
    Nat Rev Cardiol; 2013 Nov; 10(11):618-9. PubMed ID: 24019032
    [No Abstract]   [Full Text] [Related]  

  • 19. [PCSK9 inhibitors: emerging treatment to lower cholesterol?].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2014 Mar; 10(420):539-42, 544. PubMed ID: 24701672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.
    Sahebkar A
    Nat Rev Cardiol; 2014 Jan; 11(1):12. PubMed ID: 24217159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.